Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research

Novimmune, LegoChem to collaborate on antibody drug conjugate research

Published 14 February 2017

Swiss biotech company Novimmune and South Korea based LegoChem Biosciences (LCB) have entered into a research collaboration to evaluate an antibody drug conjugate candidate.

LCB has been successfully developing global partnerships through the potential of its proprietary ADC platform technology.

In 2015, LCB out-licensed an anti-Her2-ADC molecule to Fosun Pharma and in January 2017, signed a research licensing deal with Takeda, to evaluate next-generation ADC candidates.

Novimmune Chairman and CEO Eduard Holdener said: “Our antibody expertise married with LCB’s proprietary ADC technology, supports our quest to provide better options to cancer patients.”

ADCs are molecules composed of a tumor specific monoclonal antibody linked to a cytotoxic agent. Unlike chemotherapy, they are intended to target only cancer cells and spare healthy cells.

Novimmune brings expertise in the field of targeted therapies with their anti-CD47/anti-CD19 and anti-CD47/anti-mesothelin bispecific antibodies that selectively bind to hematological and solid tumors, respectively.



Source: Company Press Release